# Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients

> **NCT03876028** · PHASE1 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 10 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** Tisagenlecleucel
- **DRUG:** Ibrutinib

## Key facts

- **NCT ID:** NCT03876028
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-11
- **Primary completion:** 2021-11-01
- **Final completion:** 2021-11-01
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** Business reasons
- **Last updated:** 2023-01-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03876028

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03876028, "Study of Tisagenlecleucel in Combination With Ibrutinib in r/r Diffuse Large B-cell Lymphoma Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT03876028. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*